UVIC Stock News 6.1000 05/08/2014 16:05:19 Unilens Vision Inc

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Unilens Vision Inc (UVIC) 6.1000 $UVIC

Unilens Vision Inc. Declares Quarterly Cash Dividend Of $0.045 Per Share
PR Newswire - Thu May 01, 10:05AM CDT
The Unilens Vision Inc. (OTC Markets Group OTCQB: UVIC) Board of Directors today declared the 31st consecutive quarterly cash dividend, payable May 23, 2014 at $0.045 per common share to stockholders of record at the close of business on May 12, 2014.

Unilens Vision Inc. Reports Operating Results for Second Quarter of FY2014
Marketwire - Fri Feb 14, 7:28AM CST
Unilens Vision Inc. (OTCQB: UVIC), which develops, licenses, manufactures, distributes and markets specialty contact lenses, today reported its operating results for the second quarter and first half of FY2014.

Unilens Vision Inc. Reports Operating Results for First Quarter of FY2014
Marketwire - Thu Nov 14, 7:28AM CST
Unilens Vision Inc. (OTCQB: UVIC), which develops, licenses, manufactures, distributes and markets specialty contact lenses, today reported its operating results for the first quarter of FY2014.

Unilens Vision Reports Third Quarter Operating Results
Marketwire - Wed May 15, 7:28AM CDT
Unilens Vision Inc. (OTCQB: UVIC) (TSX VENTURE: UVI), which develops, licenses, manufactures, distributes and markets specialty contact lenses, today reported its operating results for the third quarter and first nine months of FY2013.

Unilens Modifies License Agreement With Bausch + Lomb - Grants Right To Use Next Generation Multifocal Technology
PR Newswire - Thu Apr 11, 8:00AM CDT
Unilens Vision Inc. (OTC Markets Group OTCQB: UVIC) (TSX Venture Exchange: UVI), through it's wholly owned subsidiary Unilens Vision Sciences Inc. today announced that the company and Bausch + Lomb have extended the parties' existing licensing agreement.

Unilens Vision Announces National Roll-Out of Disposable C-Vue(R) HydraVUE(TM) Multifocal Silicone Hydrogel Contact Lenses
Marketwire - Thu Feb 21, 12:44PM CST
Unilens Vision Inc. (OTCQB: UVIC) (TSX VENTURE: UVI), which develops, licenses, manufactures, distributes and markets specialty contact lenses, today announced the launch of its new silicone hydrogel disposable C-Vue(R) HydraVUE(TM) Multifocal contact lens for monthly replacement. The new product continues to incorporate Unilens' highly developed, world-class patented Multifocal design technology in a silicone hydrogel material, which offers the benefit of higher oxygen transmissibility for better eye health.

Unilens Vision Reports Second Quarter Operating Results
Marketwire - Thu Feb 14, 7:28AM CST
Unilens Vision Inc. (OTCQB: UVIC) (TSX VENTURE: UVI), which develops, licenses, manufactures, distributes and markets specialty contact lenses, today reported its operating results for the second quarter and first half of FY2013.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Important Legal Opportunity for Coinbase Investors in Class Action

Updated Category News Views 114

Key Opportunity for Coinbase Investors Investors holding Coinbase Global, Inc. (NASDAQ: COIN) securities may have a significant opportunity to participate in a class action lawsuit alleging serious violations of securities regulations. This opportunity arises from actions that took place during the specified Class Period. Investors are encouraged to evaluate their...

Continue Reading
BridGene Biosciences Secures $28 Million for Drug Development

Updated Category News Views 244

BridGene Biosciences Raises Significant Funding BridGene Biosciences, Inc., renowned for its innovative approach in developing small molecule drugs, recently announced the completion of a substantial $28 million Series B+ financing round. This funding round was spearheaded by Bayland Capital, alongside notable contributions from GTJA Investment Group, Proxima Ventures,...

Continue Reading
NMD Pharma Breaks Ground with NMD670 in Rare Neuromuscular Treatment

Updated Category News Views 177

NMD Pharma's Innovative Phase 2 Study with NMD670 NMD Pharma A/S, an ambitious clinical-stage biotech company, is making strides in the fight against neuromuscular diseases. They have officially begun their Phase 2a clinical trial of NMD670, a novel treatment aimed at addressing the challenges faced by patients with Charcot-Marie-Tooth (CMT) disease types 1 and 2. This...

Continue Reading
Becker Milk Company Limited Announces Half-Year Financial Overview

Updated Category News Views 89

Introduction to Becker Milk Company's Financial Landscape Becker Milk Company Limited is making headlines with its financial results for the first half of its fiscal year. The latest report showcases their performance, reflecting on revenues and net income trends. Financial Highlights Overview Total revenues for the first six months reveal a detail-oriented insight into...

Continue Reading
Mini Melts Collaborates with 7-Eleven for Blue Raspberry Flavor

Updated Category News Views 354

Exciting New Flavor Launch from Mini Melts and 7-Eleven In an exciting collaboration, Mini Melts USA, a leader in premium beaded ice cream, has partnered with 7-Eleven, Inc. to introduce a new flavor reminiscent of the classic Blue Raspberry Slurpee. This innovative flavor captures the essence of the much-loved frozen drink, providing fans with a delightful and nostalgic...

Continue Reading